Regenerx Biopharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Regenerx Biopharmaceuticals Inc (RGRX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Regenerx Biopharmaceuticals Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 561,943M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+0.0% annualized vs trailing 12 months), vs decelerating (-29.9%) for its tracked peer group.
- Growth: Regenerx Biopharmaceuticals Inc generated 0.0% revenue growth year over year in Q1 2023, vs 36.7% for its tracked competitors combined.
- Profitability: Its -2,007.3% net margin compares with 9.7% for the peer group.
- Peer revenue share: Regenerx Biopharmaceuticals Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.01M compares with $0.96M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
RGRX Sales vs. its Competitors, Q1 2023
Regenerx Biopharmaceuticals Inc reported revenue contraction of 0.01 % year on year in Q1 2023, below its competitors' combined revenue growth of 36.65 %.
With a net margin of -2,007.30 %, Regenerx Biopharmaceuticals Inc reported lower profitability than its competitors (9.70 %).
Regenerx Biopharmaceuticals Inc generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
Regenerx Biopharmaceuticals Inc vs. its Competitors, Q1 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Regenerx Biopharmaceuticals Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Regenerx Biopharmaceuticals Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Regenerx Biopharmaceuticals inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Regenerx Biopharmaceuticals Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.1% year over year, combined, vs 0.0% for Regenerx Biopharmaceuticals Inc. Regenerx Biopharmaceuticals Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Regenerx Biopharmaceuticals Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Regenerx Biopharmaceuticals inc | - | No | No | Yes |
| Competitors combined (101) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
RGRX Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Nurix Therapeutics Inc | 282.9% | Outperformed |
| 3 | Omeros Corporation | 282.9% | Outperformed |
| 4 | Puma Biotechnology Inc | 282.9% | Outperformed |
| 5 | Teva Pharmaceutical Industries Limited | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Regenerx Biopharmaceuticals Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Regenerx Biopharmaceuticals inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Regenerx Biopharmaceuticals inc | 0.16 | 0.08 |
| Eli Lilly And Company | 1,138,091.20 | 79,665.80 |
| Johnson and Johnson | 645,965.17 | 99,335.00 |
| Merck and Co Inc | 358,767.50 | 66,569.00 |
| Novartis Ag | 295,439.60 | 56,674.00 |
| Astrazeneca Plc | 267,867.38 | 58,739.00 |
| SUBTOTAL | 3,571,210.83 | 562,498.35 |
Sign in to see all competitors of Regenerx Biopharmaceuticals inc .
Sources: Regenerx Biopharmaceuticals inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Regenerx Biopharmaceuticals inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Regenerx Biopharmaceuticals Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Regenerx Biopharmaceuticals inc .
Regenerx Biopharmaceuticals Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Regenerx Biopharmaceuticals inc | 0 | 12,793 | -281,432 |
| Eli Lilly And Company | 1,138,091 | 1,593,316 | 534,224 |
| Johnson and Johnson | 645,965 | 705,504 | 114,311 |
| Merck and Co Inc | 358,768 | 887,587 | 42,267 |
| Novartis Ag | 295,440 | 752,973 | 185,566 |
| Astrazeneca Plc | 267,867 | 706,847 | 123,141 |
| PEERS TOTAL | 3,571,211 | 956,317 | 143,242 |
Sign in to see all peers for Regenerx Biopharmaceuticals inc .
Regenerx Biopharmaceuticals Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 23.60 % |
| Gilead Sciences Inc | United States 70.78 % |
| Vertex Pharmaceuticals Inc | United States 61.68 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Regenerx Biopharmaceuticals inc .
Regenerx Biopharmaceuticals Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 497 companies in Regenerx Biopharmaceuticals Inc's industry classification, broader than the peer set above. Market cap in millions of $.Regenerx Biopharmaceuticals Inc ranks #0 of 497 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 861, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,138,091 | 20.36 % |
| 2 | Johnson and Johnson | 643,723 | 11.52 % |
| 3 | Beone Medicines Ltd | 568,470 | 10.17 % |
| 4 | Abbvie Inc | 505,868 | 9.05 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 0 | Regenerx Biopharmaceuticals inc | 0 | 0.00 % |
Market cap and industry share for the rest of Regenerx Biopharmaceuticals Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-10-22.
Regenerx Biopharmaceuticals Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (456 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 42.51 % (avg) | -42.5 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -6.83 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 0.00 % | 7.04 % (avg) | -7.0 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Regenerx Biopharmaceuticals Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (456 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.2x | - |
| EV / EBITDA | - | 15.9x | - |
| P/B | -5.7x | 4.3x | -10.0x |
| Return on Equity | 51.20 % | industry aggregate | 38.00 % |
| Return on Invested Capital | 77.38 % | -4.07 % (avg) | 81.45 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Regenerx Biopharmaceuticals Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | 53.94 % | -39.28 % | 22.97 % | 10.18 % | 0.00 % | 0.00 % | 0.00 % |
| Operating Margin | -2,820.46 % | -1,794.08 % | -2,550.01 % | -1,899.56 % | -1,643.89 % | - | - | - |
| Return on Invested Capital | 34.04 % | 23.75 % | 21.82 % | 65.18 % | 94.62 % | 124.45 % | -210.27 % | 154.89 % |
| P/E | - | 116.5x | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Regenerx Biopharmaceuticals Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 861 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 7.04 % (see Profitability & Cost Structure above) |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments. Supplier power and buyer power are not assessed here -- see Regenerx Biopharmaceuticals Inc's dedicated Suppliers and Customers pages for concentration data; threat of substitutes has no systematic data source in this system and is not estimated.
Regenerx Biopharmaceuticals Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 38.0 points above the industry aggregate.
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (48.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-29.9% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Regenerx Biopharmaceuticals Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Regenerx Biopharmaceuticals inc | 0.48 | 0.51 | - |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
Sign in to see all peers for Regenerx Biopharmaceuticals inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Regenerx Biopharmaceuticals Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Regenerx Biopharmaceuticals inc | Q1 2023 | 0.0 % | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| PEERS TOTAL | +10.5 % | -30.4 % |
Sign in to see all peers for Regenerx Biopharmaceuticals inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Regenerx Biopharmaceuticals Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Regenerx Biopharmaceuticals inc | Q1 2023 | - | - |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
Sign in to see all peers for Regenerx Biopharmaceuticals inc .
Regenerx Biopharmaceuticals Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Regenerx Biopharmaceuticals inc | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
Sign in to see all peers for Regenerx Biopharmaceuticals inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Regenerx Biopharmaceuticals Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Regenerx Biopharmaceuticals inc | - | 2.06 |
| Eli Lilly And Company | 42.75 | 14.29 |
| Johnson and Johnson | 39.91 | 6.50 |
| Merck and Co Inc | 117.14 | 5.39 |
| Novartis Ag | 21.13 | 5.21 |
| Astrazeneca Plc | 26.20 | 4.56 |
| PEERS AVERAGE | 42.39 | 6.35 |
Sign in to see all peers for Regenerx Biopharmaceuticals inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.